AMANDA KASSAB: Open Payments
NPI 1760188312 · WEST BLOOMFIELD, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$983 in 42 payments from 9 companies in 2025. Trend: 2023 $390 · 2024 $407 · 2025 $983
Food & beverage: $984
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 20 | $596 |
| Verona Pharma, Inc. | 13 | $204 |
| Lundbeck LLC | 2 | $40 |
| Alkermes, Inc. | 1 | $33 |
| Lilly USA, LLC | 2 | $32 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Novo Nordisk Inc | 1 | $20 |
| GlaxoSmithKline, LLC. | 1 | $19 |
| Orexo US, Inc. | 1 | $17 |
Products named: Ohtuvayre, AIRSUPRA, REXULTI, LYBALVI, CAPLYTA, Wegovy, TRELEGY ELLIPTA, Zubsolv.
Industry payments across MI — which companies pay providers there.
